Botulinum Toxin for Bruxism: Evidence and Injection

Bruxism, the involuntary clenching and grinding of the teeth, affects a substantial proportion of adults and children and is a major cause of tooth wear, muscle pain, headache, and temporomandibular disorders. Conventional management relies on occlusal splints, behavioral modification, and muscle...

Bruxism, the involuntary clenching and grinding of the teeth, affects a substantial proportion of adults and children and is a major cause of tooth wear, muscle pain, headache, and temporomandibular disorders. Conventional management relies on occlusal splints, behavioral modification, and muscle relaxants, but these measures are often only partially effective. In recent years, botulinum toxin type A has emerged as a targeted biological treatment that reduces the excessive contraction of the masseter and temporalis muscles, and a growing body of evidence supports its use in carefully selected cases. This article reviews that evidence and describes the injection technique.

The Rationale for Botulinum Toxin

How Botulinum Toxin Works

Botulinum toxin type A is a neurotoxin that blocks the release of acetylcholine at the neuromuscular junction, producing a temporary, dose-dependent weakening of the injected muscle. When delivered into the masseter, the toxin reduces the force of clenching, decreases the frequency of grinding episodes, and relieves the muscle fatigue and pain that accompany chronic bruxism. The effect is not permanent; it typically begins within a few days, peaks at around two to four weeks, and lasts for three to six months, after which the injection must be repeated.

Why Target the Masseter

The masseter is the principal muscle of clenching and the main generator of bite force, so reducing its activity produces the greatest clinical benefit with the least effect on speech and swallowing. The temporalis is injected as well when clinical examination reveals hypertrophy or tenderness in that region. By weakening the overactive muscles rather than altering the occlusion, the toxin offers an advantage over splints, which protect the teeth but do not reduce the underlying muscle activity.

The Evidence Base

Randomized Controlled Trials

The evidence for botulinum toxin in bruxism has accumulated through a series of randomized and controlled studies. A landmark randomized controlled trial by Lee and colleagues, published in the Journal of Oral Rehabilitation in 2010, treated adults with severe bruxism and reported that injections of botulinum toxin type A into the masseter significantly reduced the frequency of bruxism events and the pain scores compared with placebo, with the benefits persisting for several months after the injection. Similar findings were reported by Patel and colleagues in 2016, who observed a reduction in both the subjective symptoms and the objective measures of muscle activity.

Meta-Analyses and Outcome Measures

Pooled analyses have strengthened the conclusion that botulinum toxin reduces bruxism-related outcomes. A meta-analysis published in the Journal of Oral Rehabilitation in 2017, which combined data from several controlled trials, concluded that botulinum toxin type A was associated with significant reductions in pain intensity, the number of bruxism episodes per hour of sleep, and the maximum voluntary bite force. The trials consistently report reductions in bite force of roughly 20 to 30 percent following treatment, a change that is large enough to protect the teeth and joints while preserving the ability to chew normally.

Study	Design	Key finding
Lee et al. (2010)	Randomized controlled trial	Reduced bruxism events and pain vs placebo
Patel et al. (2016)	Controlled study	Reduced symptoms and muscle activity
Meta-analysis (2017)	Pooled controlled trials	Significant fall in pain, episodes, bite force

Patient Selection

Who Benefits Most

The best candidates for botulinum toxin are adults with moderate to severe bruxism that has failed to respond to conventional treatment, particularly those with marked masseter hypertrophy, nocturnal grinding that is confirmed by a partner or by polysomnography, and pain that is clearly muscular in origin. Patients with a myofascial component of temporomandibular disorder often report substantial relief, because the toxin addresses the muscle spasm that drives their pain. The treatment is also valuable when bruxism has already produced significant tooth wear or failed occlusal splint therapy.

Contraindications and Cautions

Botulinum toxin is contraindicated in pregnancy and breastfeeding, in patients with disorders of the neuromuscular junction such as myasthenia gravis, and in those taking aminoglycoside antibiotics, which can potentiate the effect of the toxin. Patients with unrealistic expectations, unstable psychological conditions, or a history of allergy to the toxin should not be treated. It is essential to explain that the treatment is symptomatic, that it does not cure the underlying cause of bruxism, and that repeat injections will be required, so that the patient consents with a full understanding of the benefits and the limitations.

Criterion	Consideration
Moderate to severe bruxism	Failed conventional treatment
Masseter hypertrophy	Visible and palpable enlargement
Myofascial pain	Muscular component of TMD
Pregnancy or breastfeeding	Contraindicated
Neuromuscular disease	Contraindicated

The Injection Technique

Dosage and Reconstitution

The toxin is supplied as a lyophilized powder that is reconstituted with preservative-free saline to a standard concentration. For bruxism, a typical dose is 25 to 30 units per masseter, distributed across three to five injection points, with a lower dose of 15 to 20 units used in the temporalis when indicated. The total dose is individualized according to the muscle bulk, the severity of the condition, and the response to previous treatment, and it is prudent to begin with a conservative dose to avoid excessive weakening of the muscles of mastication.

Injection Sites and Safety

The masseter is injected at the points of maximal muscle bulk, identified by asking the patient to clench, and the injection is delivered into the belly of the muscle rather than superficially, to avoid diffusion into the facial muscles. The clinician palpates the anterior border of the muscle, the angle of the mandible, and the zygomatic arch to define a safe zone, and injections are placed at least one centimeter above the lower border of the mandible and at least one centimeter behind the anterior border, to avoid the facial artery and the marginal mandibular nerve. The same careful mapping applies to the temporalis.

Anatomic landmark	Safety measure
Lower border of mandible	Keep injections ≥1 cm above
Anterior border of masseter	Keep injections ≥1 cm behind
Facial artery	Avoid the anterior-inferior zone
Marginal mandibular nerve	Avoid the lower border

Adverse Effects and Management

Common Side Effects

The procedure is generally well tolerated, and the most common adverse effects are transient and local: mild injection-site pain, bruising, and swelling, which resolve within a few days. Muscle weakness is the principal risk, and if the toxin diffuses into adjacent muscles the patient may develop an asymmetric smile, difficulty with chewing, or a temporary change in speech, particularly when the dose is too high or the injection is placed too superficially. These effects are temporary and resolve as the toxin wears off, usually within two to three months.

Rare Complications and Follow-up

Rare complications include infection at the injection site, an allergic reaction, and a paradoxical increase in symptoms if the toxin is placed incorrectly. The patient is reviewed at two to four weeks to assess the response, and the dose is adjusted for the next treatment. Because the effect is reversible, the treatment offers the clinician the opportunity to fine-tune the dose over successive cycles, and most patients who respond well continue with injections every three to six months as part of their ongoing management of bruxism.

Clinical Key Points

- Botulinum toxin type A reduces masseter activity by blocking acetylcholine release.

- Controlled trials and meta-analyses show significant reductions in bruxism events and pain.

- The best candidates are adults with severe bruxism refractory to conventional care.

- Typical dosing is 25–30 units per masseter, three to five points.

- Anatomic landmarks protect the facial artery and the marginal mandibular nerve.

- The effect is reversible and lasts three to six months.

Conclusion

Botulinum toxin type A has earned a firm place in the modern management of bruxism, offering a biological approach that targets the overactive muscle rather than merely protecting the teeth. The evidence from controlled trials and meta-analyses supports its effectiveness in reducing grinding, pain, and bite force, and careful patient selection and precise injection technique keep the risks low. When used as part of a comprehensive plan that includes splint therapy, stress management, and regular review, botulinum toxin provides durable relief for patients whose bruxism has resisted every other measure.